Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Maps Stats
#1 / 27 Total
VQS - VIQ Solutions Inc - Stock Price Chart
TickerVQS [NASD]
CompanyVIQ Solutions Inc
CountryCanada
IndustrySoftware - Application
Market Cap7.78MEPS (ttm)-0.31
P/E-EPS this Y-3.57%
Forward P/E-EPS next Y39.66%
PEG-EPS past 5Y-6.58%
P/S0.18EPS next 5Y-
P/B0.57EPS Q/Q8.42%
Dividend-Sales Q/Q-14.84%
Insider Own30.39%Inst Own2.49%
Insider Trans0.00%Inst Trans-
Short Float0.64%EarningsAug 14/a
Analyst Recom1.00Target Price0.75
Avg Volume121.71K52W Range0.11 - 0.76
Today 07:38AM Why Is VIQ Solutions (VQS) Stock Up 57% Today? (InvestorPlace) +45.88%
Sep-27-23 05:30PM VIQ Solutions Announces Delisting from Nasdaq and Director Resignation (Business Wire)
Aug-14-23 07:00PM VIQ Solutions Announces Second Quarter 2023 Financial Results (Business Wire)
Aug-08-23 07:00PM VIQ Solutions to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023 (Business Wire) -5.21%
Aug-02-23 07:30AM VIQ Solutions Closes Oversubscribed Private Placement Financing (Business Wire)
Jul-27-23 07:45AM VIQ Solutions Announces Draw on Previously Announced US$15 Million Credit Facility (Business Wire) -6.24%
Jul-14-23 09:58AM VIQ Solutions Inc. (TSE:VQS) Surges 45% Yet Its Low P/S Is No Reason For Excitement (Simply Wall St.)
Jun-27-23 06:00PM VIQ Solutions Announces Voting Results From Annual and Special Meeting of Shareholders (Business Wire)
Jun-15-23 07:30AM VIQ Solutions Signs Strategic Partnership with JAVS to Modernize Courtroom Documentation Using AI (Business Wire) +39.08%
Jun-06-23 07:30AM VIQ Solutions Wins 2023 Fortress Cyber Security Award for Data Protection (Business Wire)
ALXO - Alx Oncology Holdings Inc - Stock Price Chart
TickerALXO [NASD, RUT]
CompanyAlx Oncology Holdings Inc
CountryUSA
IndustryBiotechnology
Market Cap324.67MEPS (ttm)-3.19
P/E-EPS this Y-4.40%
Forward P/E-EPS next Y-5.58%
PEG-EPS past 5Y-58.82%
P/S-EPS next 5Y-
P/B1.52EPS Q/Q-3.29%
Dividend-Sales Q/Q-
Insider Own55.28%Inst Own44.42%
Insider Trans-0.06%Inst Trans1.24%
Short Float16.48%EarningsAug 10/a
Analyst Recom1.33Target Price27.83
Avg Volume160.07K52W Range3.94 - 13.64
Today 06:00AM ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire) +64.03%
Oct-02-23 04:05PM ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Sep-06-23 08:00AM ALX Oncology Realigns Executive Leadership Team (GlobeNewswire) +6.37%
Aug-31-23 07:00AM ALX Oncology Announces September Investor Conference Participation (GlobeNewswire)
Aug-14-23 07:31PM While dollars continue to flow into biotech, companies cut more jobs (American City Business Journals)
Aug-10-23 04:01PM ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update (GlobeNewswire)
09:55AM ALX Oncology Holdings Inc. (ALXO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Jun-26-23 07:00AM ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer (GlobeNewswire)
May-11-23 04:01PM ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
May-09-23 07:00AM ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer (GlobeNewswire) +6.36%
MKUL - Molekule Group Inc - Stock Price Chart
TickerMKUL [NASD]
CompanyMolekule Group Inc
CountryUSA
IndustryPollution & Treatment Controls
Market Cap8.74MEPS (ttm)-1.01
P/E-EPS this Y-319.05%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.40EPS next 5Y-
P/B0.21EPS Q/Q-103.12%
Dividend-Sales Q/Q18573.62%
Insider Own55.91%Inst Own18.95%
Insider Trans0.00%Inst Trans-49.19%
Short Float0.55%EarningsAug 16/b
Analyst Recom3.00Target Price7.00
Avg Volume401.97K52W Range0.13 - 5.98
Aug-24-23 07:00AM Molekule's PECO technology demonstrates power of pollutant destruction in air purification (GlobeNewswire) -16.20%
Aug-16-23 07:00AM Molekule Reports Second Quarter 2023 Financial Results (GlobeNewswire) -12.36%
Aug-06-23 10:02AM The past year for Molekule Group (NASDAQ:MKUL) investors has not been profitable (Simply Wall St.)
Jul-18-23 07:00AM Molekule launches Molekule 360, first-of-its-kind indoor air quality management solution (GlobeNewswire) +8.25%
Jun-27-23 07:00AM Test Results Indicate that Molekules Air Pro Purifier Reduces Hospital Length of Stay by Approximately Two Days in COVID-19 Patients (GlobeNewswire)
May-16-23 07:30AM Molekule Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-08-23 07:30PM Molekule Group, Inc. Announces Closing of $10.0 Million Private Placement and Deferral of $6.0 million Principal Amortization Through 2025 (GlobeNewswire)
May-04-23 09:25AM Molekule Signs Agreement to Provide Air Quality Monitoring Services to Veterans Affairs Facilities (GlobeNewswire)
May-03-23 09:15AM Molekule Group, Inc. Announces $10.0 Million Private Placement And Amends Loan Agreements to Defer Approximately $6.1 Million of Principal Payments Originally Scheduled for 2023, 2024 and Q1 2025 (GlobeNewswire)
Apr-28-23 09:00AM Molekule and Aura Expand in Global Education Market with Multiple Deployments and Orders (GlobeNewswire) +22.96%
SPRC - SciSparc Ltd - Stock Price Chart
TickerSPRC [NASD]
CompanySciSparc Ltd
CountryIsrael
IndustryBiotechnology
Market Cap84.62MEPS (ttm)-1.33
P/E-EPS this Y-2371.07%
Forward P/E-EPS next Y-6.96%
PEG-EPS past 5Y-62.50%
P/S62.68EPS next 5Y-
P/B6.92EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own0.92%Inst Own0.05%
Insider Trans0.00%Inst Trans-
Short Float0.12%Earnings-
Analyst Recom1.00Target Price520.00
Avg Volume166.72K52W Range3.15 - 41.34
Today 07:33AM SciSparc Granted European Patent for its Core Technology (GlobeNewswire) +78.26%
Sep-29-23 07:45AM SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder (GlobeNewswire) -7.16%
Sep-27-23 07:58AM SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split (GlobeNewswire) +32.86%
Sep-20-23 06:30AM SciSparc Announces 1-for-26 Reverse Share Split (GlobeNewswire) +14.14%
Sep-12-23 09:15AM SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities (GlobeNewswire) +6.38%
Sep-07-23 09:15AM SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome (GlobeNewswire)
06:00AM SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement (GlobeNewswire)
Aug-15-23 09:50AM Aegis Capital Corp. acted as Sole Bookrunner on a $1.3 Million Underwritten Public Offering for SciSparc Ltd. (NASDAQ: SPRC) (ACCESSWIRE)
Aug-14-23 12:20PM SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering (GlobeNewswire)
Aug-10-23 09:10AM SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering (GlobeNewswire) -62.83%
PNT - POINT Biopharma Global Inc - Stock Price Chart
TickerPNT [NASD, RUT]
CompanyPOINT Biopharma Global Inc
CountryUSA
IndustryBiotechnology
Market Cap1.30BEPS (ttm)0.87
P/E14.16EPS this Y-
Forward P/E-EPS next Y-16.93%
PEG-EPS past 5Y-
P/S5.40EPS next 5Y-
P/B2.91EPS Q/Q11.84%
Dividend-Sales Q/Q-
Insider Own18.65%Inst Own56.43%
Insider Trans0.00%Inst Trans24.86%
Short Float8.17%EarningsAug 14/b
Analyst Recom1.08Target Price16.90
Avg Volume537.47K52W Range5.59 - 11.13
Today 06:45AM Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies (PR Newswire) +83.99%
Sep-18-23 08:00AM POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands (GlobeNewswire)
Aug-14-23 07:30AM POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Jul-31-23 09:00AM ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177 (GlobeNewswire)
Jun-26-23 07:45AM POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands (GlobeNewswire) -10.28%
07:30AM POINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMIs Annual Congress (GlobeNewswire)
Jun-12-23 08:00AM POINT Biopharma Announces Appointment of Dr. Bridget Martell to its Board of Directors (GlobeNewswire)
Jun-07-23 07:00AM POINT Biopharma to Host Virtual Investor Day on Tuesday, June 20, 2023 (GlobeNewswire)
May-25-23 08:30AM POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO (GlobeNewswire)
May-15-23 07:35AM POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope Manufacturer (GlobeNewswire) +9.83%
DXYN - Dixie Group Inc. - Stock Price Chart
TickerDXYN [NASD]
CompanyDixie Group Inc.
CountryUSA
IndustryTextile Manufacturing
Market Cap6.79MEPS (ttm)-2.05
P/E-EPS this Y-
Forward P/E1.34EPS next Y40.00%
PEG-EPS past 5Y-30.69%
P/S0.02EPS next 5Y-
P/B0.26EPS Q/Q60.43%
Dividend-Sales Q/Q-11.58%
Insider Own13.51%Inst Own35.84%
Insider Trans0.00%Inst Trans-20.24%
Short Float0.35%Earnings-
Analyst Recom2.00Target Price5.00
Avg Volume18.28K52W Range0.62 - 1.36
Aug-05-23 08:59AM The Dixie Group, Inc. (NASDAQ:DXYN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-04-23 11:16PM Q2 2023 Dixie Group Inc Earnings Call (Thomson Reuters StreetEvents)
10:37AM Dixie Group: Q2 Earnings Snapshot (AP Finance)
09:25AM The Dixie Group Reports Operating Income for Second Quarter of 2023 (ACCESSWIRE)
Jul-31-23 05:10PM The Dixie Group 2023 Q2 Earnings Release and Conference Call (ACCESSWIRE) -6.26%
Jul-26-23 05:11PM The Dixie Group Announces Termination of Sale and Leaseback Agreement (ACCESSWIRE)
Jun-06-23 04:05PM The Dixie Group Announces Sale and Leaseback of Distribution Facility (ACCESSWIRE)
May-05-23 02:32AM Q1 2023 Dixie Group Inc Earnings Call (Thomson Reuters StreetEvents) +6.41%
May-04-23 10:45AM The Dixie Group Reports Operating Income for First Quarter of 2023 (ACCESSWIRE) +11.11%
10:19AM Dixie Group: Q1 Earnings Snapshot (AP Finance)
SSU - SIGNA Sports United N.V. - Stock Price Chart
TickerSSU [NYSE]
CompanySIGNA Sports United N.V.
CountryGermany
IndustrySpecialty Retail
Market Cap60.46MEPS (ttm)-1.78
P/E-EPS this Y74.34%
Forward P/E-EPS next Y53.19%
PEG-EPS past 5Y-
P/S0.05EPS next 5Y-
P/B0.09EPS Q/Q-
Dividend-Sales Q/Q3.26%
Insider Own56.98%Inst Own7.53%
Insider Trans0.00%Inst Trans-0.54%
Short Float0.12%EarningsJun 28/b
Analyst Recom3.00Target Price3.87
Avg Volume345.48K52W Range0.14 - 6.40
Oct-02-23 07:30AM SIGNA Sports United N.V. Accelerates Strategic Realignment and Restructuring Program (Business Wire) -43.73%
Jul-17-23 06:00AM SIGNA Sports United N.V. Announces Appointment of Anthonie Anbeek to the Board of Directors Effective April 1st, 2024 (Business Wire)
Jun-28-23 07:30AM SIGNA Sports United N.V. Reports H1 FY23 Results (Business Wire) -11.25%
Jun-21-23 04:00PM SIGNA Sports United to Announce Second Quarter Fiscal 2023 Financial Results on 28 June 2023 (Business Wire)
Mar-16-23 07:00AM SIGNA Sports United Q1 FY23 Trading Update (Business Wire)
Feb-21-23 04:30PM SIGNA Sports United Annual Report on Form 20-F for Fiscal Year Ended September 30, 2022 (Business Wire) -5.00%
Feb-07-23 07:00AM SIGNA Sports United Reports Q4 FY22 and FY22 Results (Business Wire)
Feb-01-23 11:30AM Signa Sports United to Announce Fourth Quarter and Full Year Fiscal 2022 Financial Results on February 7, 2023 (Business Wire)
Oct-27-22 09:05AM Signa Sports United Announces Conference Participation for November 2022 (Business Wire)
Aug-18-22 09:00AM SIGNA Sports United Announces Participation in Upcoming Investor Conferences (Business Wire) +8.77%
MAIA - MAIA Biotechnology Inc - Stock Price Chart
TickerMAIA [AMEX]
CompanyMAIA Biotechnology Inc
CountryUSA
IndustryBiotechnology
Market Cap29.07MEPS (ttm)-1.59
P/E-EPS this Y12.57%
Forward P/E-EPS next Y-5.88%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B4.23EPS Q/Q12.94%
Dividend-Sales Q/Q-
Insider Own36.62%Inst Own2.36%
Insider Trans4.62%Inst Trans-
Short Float0.24%EarningsAug 08/b
Analyst Recom1.00Target Price12.62
Avg Volume37.64K52W Range1.42 - 5.22
Today 08:01AM MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer (Business Wire) -16.14%
Sep-28-23 08:01AM MAIA Biotechnology Announces Share Repurchase Program (Business Wire) +11.80%
Aug-21-23 09:55AM MAIA Biotechnology, Inc. (MAIA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-15-23 10:20AM Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-08-23 08:00AM MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer (Business Wire)
Jul-11-23 08:00AM MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer (Business Wire)
Jul-10-23 08:00AM MAIA Biotechnology Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer (Business Wire)
Jun-20-23 08:00AM MAIA Biotechnology Announces Updates in Enrollment in Phase II Clinical Trial: THIO-101 Has Enrolled 29 Patients (Business Wire) -9.44%
Jun-07-23 08:00AM MAIA Biotechnology Files Second Patent For New Telomere-Targeting Molecules Program (Business Wire)
May-08-23 08:00AM MAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate Update (Business Wire) -6.69%
RDHL - Redhill Biopharma Ltd. ADR - Stock Price Chart
TickerRDHL [NASD]
CompanyRedhill Biopharma Ltd. ADR
CountryIsrael
IndustryDrug Manufacturers - Specialty & Generic
Market Cap3.12MEPS (ttm)-3.09
P/E-EPS this Y-2566.67%
Forward P/E-EPS next Y50.00%
PEG-EPS past 5Y15.13%
P/S0.09EPS next 5Y-
P/B0.45EPS Q/Q-
Dividend-Sales Q/Q-90.21%
Insider Own0.50%Inst Own5.91%
Insider Trans0.00%Inst Trans-73.32%
Short Float0.10%EarningsAug 17/b
Analyst Recom1.00Target Price7.75
Avg Volume398.53K52W Range0.45 - 38.40
Today 07:00AM RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study (PR Newswire) +18.07%
Sep-22-23 04:15PM RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency (PR Newswire)
Sep-18-23 07:00AM RedHill Announces FDA sNDA Approval for Talicia® (PR Newswire)
Sep-05-23 07:00AM RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®) (PR Newswire)
Aug-17-23 07:00AM RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights (PR Newswire) +13.41%
Aug-01-23 07:00AM RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S. (PR Newswire)
Jul-31-23 07:00AM RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA (PR Newswire)
Jul-25-23 03:58PM RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise (PR Newswire)
Jul-21-23 09:33AM RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds (PR Newswire) -25.95%
07:00AM RedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development (PR Newswire)
VERY - Vericity Inc - Stock Price Chart
TickerVERY [NASD]
CompanyVericity Inc
CountryUSA
IndustryInsurance - Life
Market Cap166.11MEPS (ttm)-0.83
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-27.42%
P/S0.97EPS next 5Y-
P/B1.44EPS Q/Q-
Dividend-Sales Q/Q4.57%
Insider Own84.98%Inst Own1.47%
Insider Trans0.00%Inst Trans0.45%
Short Float0.17%Earnings-
Analyst Recom-Target Price-
Avg Volume2.96K52W Range4.70 - 9.28
Today 07:36AM iA Financial Corporation Strengthens Individual Insurance Presence in the United States with the Acquisition of Vericity (CNW Group) +95.85%
07:30AM iA Financial Group to Acquire Vericity in $170 million Transaction (Business Wire)
Aug-02-23 06:05AM While individual investors own 11% of Vericity, Inc. (NASDAQ:VERY), private equity firms are its largest shareholders with 76% ownership (Simply Wall St.)
Jun-08-23 12:23PM The Price Is Right For Vericity, Inc. (NASDAQ:VERY) (Simply Wall St.)
Jan-09-23 08:30AM Vericity Welcomes New Chief Marketing Officer (Business Wire)
May-25-22 07:40AM Vericity (NASDAQ:VERY) shareholders have endured a 19% loss from investing in the stock a year ago (Simply Wall St.)
Apr-08-22 12:53PM Is Vericity, Inc.'s (NASDAQ:VERY) Shareholder Ownership Skewed Towards Insiders? (Simply Wall St.)
Apr-06-22 04:07PM The Very Good Food Company Reschedules its 4th Quarter Conference Call to Thursday April 14, 2022 (PR Newswire) -5.84%
04:07PM The Very Good Food Company Reschedules its 4th Quarter Conference Call to Thursday April 14, 2022 (CNW Group)
Apr-04-22 05:00AM The Very Good Food Company Announces Management Changes and Formation of an Executive Committee (PR Newswire) +6.67%
123
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2023 FINVIZ.com. All Rights Reserved.